การทำข้อตกลงเกี่ยวกับการใช้ยา

Piyapat Owat

Authors

Piyapat Owat Pharmacy Division, Thammasat University Hospital 0009-0001-1595-6123

Keywords:

managed entry agreement, financial-based agreement, performance-based agreement

Abstract

The Managed Entry Agreement (MEA) is an agreement between the drug company and the payer that aims to enhance patients’ access to new and expensive drugs. This agreement is divided into two types, including the financial-based agreement and the performance-based agreement. The financial-based agreement aims to limit the budget impact through controlling the drug cost. This agreement is widely used because of its simplicity and uncomplicated nature. However, this agreement lacks transparency because the details contained in the agreement are confidential, causing a conflict of interest for some competitors. The performance-based agreement is based on the therapeutic effectiveness of drugs in the real world and aims to maximize utilization of new drugs and to address uncertainty about the effectiveness of new drugs. This agreement is a good practice, but complicated, and the cost of implementation is high. However, health-system decision-makers should be careful in the selection of a proper managed entry agreement to ensure efficient budgeting and equal access to drugs for patients.

References

Sakulbumrungsil R, Kessomboon N, Kanchanapibool I, Manomayitthikan T, Thathong T, Patikorn C, et al. The impact of the drug financing system under Thailand universal health coverage on the performance of the drug system. J Health Sci Thai. 2020;29(Special Issue):S59-S71.

Patikorn C, Taychakhoonavudh S, Sakulbumrungsil R, Ross-Degnan D, Anantachoti P. Financing Strategies to Facilitate Access to High-Cost Anticancer Drugs: A Systematic Review of the Literature. Int J Health Policy Manag. 2022;11(9) :1625-34.

National Drug System Development Committee. National List of Essential Medicines 2024. 2024.

ชุติมา คำดี, จิรวิชญ์ ยาดี, วิทธวัช พันธุมงคล, พรธิดา หัดโนนตุ่น, นิธิเจน กิตติรัชกุล, พัทธรา ลีฬหวรงค์, และคณะ. ผลการดำเนินงานและปัจจัยที่เกี่ยวข้องกับการคัดเลือกยาเข้าสู่บัญชี จ(2) ของบัญชียาหลักแห่งชาติ. วารสารวิจัยระบบสาธารณสุข. 2021;15(4):456-76.

Wenzl M, Chapman S. Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward. Paris, France: OECD Publishing; 2019.

Patikorn C, Taychakhoonavudh S, Thathong T, Anantachoti P. Patient access to anti-cancer medicines under public health insurance schemes in Thailand: A mixed methods study. Thai J Pharm Sci. 2019;43(3):168-78.

Dabbous M, Chachoua L, Caban A, Toumi M. Managed Entry Agreements: Policy Analysis From the European Perspective. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2020;23(4):425-33.

Klemp M, Frønsdal KB, Facey K. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care. 2011;27(1):77-83.

Organization WH. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Copenhagen: World Health Organization. Regional Office for Europe; 2015.

Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39-47.

Dabbous M, Chachoua L, Caban A, Toumi M. Managed Entry Agreements: Policy Analysis From the European Perspective. Value in Health. 2020;23(4):425-33.

Gerkens S, Neyt M, Miguel L, Vinck I, Thiry N, Cleemput I. How to improve the Belgian process for managed entry agreements?: an analysis of the Belgian and international experience. Brussel: Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE); 2017.

Grimm S, Strong M, Brennan A, Wailoo A. Framework for analysing risk in health technology assessments and its application to managed entry agreements. A report by the Decision Support Unit, ScHARR: University of Sheffield; 2016.

Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. EMiNet, Brussels, Belgium. 2013.